Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report issued on Friday. The firm set a “hold” rating on the stock.

Several other analysts have also weighed in on ONCT. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Northland Securities reiterated a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Oncternal Therapeutics Price Performance

ONCT stock opened at $0.53 on Friday. Oncternal Therapeutics has a twelve month low of $0.53 and a twelve month high of $13.14. The company has a market cap of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The business’s 50-day simple moving average is $1.12 and its 200 day simple moving average is $4.01.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.